Search
erdafitinib (Balversa)
Indications:
- treatment of advanced bladder cancer with an FGFR3 or FGFR2 aberration failing platinum-based chemotherapy
Dosage:
- starting dose of 8 mg once daily
- increase to 9 mg daily if serum phosphate < 5.5 mg/dL, between days 14 & 17.
Tabs: 3 mg, 4 mg, 5 mg
Monitor:
- serum phosphate
Adverse effects:
- central serous retinopathy or retinal pigment epithelial detachment resulting in visual field defect (25%) [3]
- increased serum phosphate, increased serum creatinine
- increased serum ALT, increased serum alkaline phosphatase
- decreased serum sodium
- stomatitis, fatigue, diarrhea, dry mouth, onycholysis
Laboratory:
- FDA-approved companion diagnostic therascreen FGFR RGQ RT-PCR Kit
Mechanism of action:
- inhibits FGF receptor
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=67462786
References
- PubChem: 67462786
- Wikipedia: Erdafitinib
https://en.wikipedia.org/wiki/Erdafitinib
- FDA News Release. April 12, 2019
FDA grants accelerated approval to erdafitinib for metastatic
urothelial carcinoma.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-erdafitinib-metastatic-urothelial-carcinoma